Looking at the universe of stocks we cover at Dividend Channel, on 12/14/17, Utah Medical Products, Inc. (UTMD - Get Report) will trade ex-dividend, for its quarterly dividend of $0.27, payable on 1/3/18. As a percentage of UTMD's recent stock price of $80.80, this dividend works out to approximately 0.33%.Below is a dividend history chart for UTMD, showing historical dividends prior to the most recent $0.27 declared by Utah Medical Products, Inc.: In general, dividends are not always predictable; but looking at the history above can help in judging whether the most recent dividend from UTMD is likely to continue, and whether the current estimated yield of 1.34% on annualized basis is a reasonable expectation of annual yield going forward. The chart below shows the one year performance of UTMD shares, versus its 200 day moving average: Looking at the chart above, UTMD's low point in its 52 week range is $58.50 per share, with $83.15 as the 52 week high point — that compares with a last trade of $80.80. In Tuesday trading, Utah Medical Products, Inc. shares are currently up about 0.3% on the day.
TheStreet’s Fundamentals of Investing Course will teach you the keys to making the right decisions in any market.
TheStreet’s Personal Finance Essentials Course will teach you money management basics and investing strategies to help you avoid major financial pitfalls.
TheStreet Courses offers dedicated classes designed to improve your investing skills, stock market knowledge and money management capabilities.
More from Stocks
How Investors Should Approach the Trade Talks, the Federal Reserve and Micron
United States Secretary of the Treasury Steven Mnuchin made comments on the trade talks early Wednesday. Mnuchin says that he believes that the U.S. and China were almost 90% of the way through trade talks. Fed chair Jerome Powell spoke about the need for the central bank to remain independent and to not cave to "short-term political interests." And, of course, we have Micron MU, which is Real Money's stock of the day and it also released earnings Tuesday after the bell. The company beat expectations.
Ear to the Ground on UTX-Raytheon: What Needs to Happen for the Deal to Close
Shareholders are skittish about this deal, one analyst said. See why they shouldn't be.
AbbVie Rebounds as Market Warms to Allergan Deal, Botox Potential
AbbVie's deal for Allergan will give it a new revenue stream in Botox, helping offset potential lower revenue from arthritis drug Humira, which is losing patent protection.
Care.com Shares Slump After Chief Financial Officer Resigns
Care.com's finance chief resigns a few months after a Wall Street Journal report that many day-care centers listed on the company's site were unlicensed.
Dow Ends Down on Mixed Trade Messages From Mnuchin, Trump
Stocks end mixed after Treasury Secretary Steven Mnuchin says the U.S. and China were close to reaching a trade agreement, while President Trump hints that he wants to make a trade deal with Beijing but is happy where things are now.